G1 Therapeutics Performance
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
G1 Therapeutics has a performance score of 19 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of -1.6, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning G1 Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, G1 Therapeutics is expected to outperform it. G1 Therapeutics today owns a risk of 0.11%. Please check out G1 Therapeutics value at risk, and the relationship between the information ratio and kurtosis , to decide if G1 Therapeutics will be following its current price history.
Risk-Adjusted Performance
19 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in G1 Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong technical indicators, G1 Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 94.7 M |
GTHX |
G1 Therapeutics Relative Risk vs. Return Landscape
If you would invest 713.00 in G1 Therapeutics on September 5, 2024 and sell it today you would earn a total of 2.00 from holding G1 Therapeutics or generate 0.28% return on investment over 90 days. G1 Therapeutics is currently generating 0.0281% in daily expected returns and assumes 0.1106% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than GTHX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
G1 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for G1 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as G1 Therapeutics, and traders can use it to determine the average amount a G1 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2538
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GTHX |
Based on monthly moving average G1 Therapeutics is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of G1 Therapeutics by adding it to a well-diversified portfolio.
G1 Therapeutics Fundamentals Growth
GTHX Stock prices reflect investors' perceptions of the future prospects and financial health of G1 Therapeutics, and G1 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GTHX Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Price To Earning | (1.95) X | |||
| Price To Book | 15.34 X | |||
| Price To Sales | 6.48 X | |||
| Revenue | 82.51 M | |||
| EBITDA | (39.01 M) | |||
| Cash And Equivalents | 143.96 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 57.17 M | |||
| Debt To Equity | 1.24 % | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.34 M) | |||
| Earnings Per Share | (0.86) X | |||
| Total Asset | 121.54 M | |||
| Retained Earnings | (779.99 M) | |||
| Current Asset | 252.33 M | |||
| Current Liabilities | 9.86 M | |||
About G1 Therapeutics Performance
Evaluating G1 Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if G1 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if G1 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.Things to note about G1 Therapeutics performance evaluation
Checking the ongoing alerts about G1 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for G1 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
- Analyzing G1 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether G1 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining G1 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating G1 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of G1 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of G1 Therapeutics' stock. These opinions can provide insight into G1 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |